Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer ' s disease published in the NEJM

STOCKHOLM, Nov. 30, 2022. BioArctic AB ' s partner Eisai announced today that the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials